About: Chapter 9 Trends in antiviral strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chapter 9 Trends in antiviral strategies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chapter 9 Trends in antiviral strategies
topic	covid:c3f6b652f5bbb394a6ca5eb515027a7ea9806e6f#this
Source	Elsevier; PMC
abstract	Abstract Viral populations are true moving targets regarding the genomic sequences to be targeted in antiviral designs. Experts from different fields have expressed the need for new paradigms for antiviral interventions and viral disease control. This chapter reviews several antiviral strategies that aim at counteracting the adaptive capacity of viral quasispecies. The proposed designs are based on combinations of different antiviral drugs and immune modulators, or in the administration of virus-specific mutagenic agents, in an approach termed lethal mutagenesis of viruses. It consists of decreasing viral fitness by an excess of mutations that render viral proteins suboptimal or nonfunctional. Viral extinction by lethal mutagenesis involves several sequential, overlapping steps that recapitulate the major concepts of intrapopulation interactions and genetic information stability discussed in preceding chapters. Despite the magnitude of the challenge, the chapter closes with some optimistic prospects for effective control of viruses displaying error-prone replication, based on the combined targeting of replication fidelity and the induction of the innate immune response.
has issue date	2020-12-31(xsd:dateTime)
bibo:doi	10.1016/b978-0-12-816331-3.00009-x
has license	els-covid
sha1sum (hex)	c3f6b652f5bbb394a6ca5eb515027a7ea9806e6f
schema:url	https://doi.org/10.1016/b978-0-12-816331-3.00009-x
resource representing a document's title	Chapter 9 Trends in antiviral strategies
has PubMed Central identifier	PMC7153320
schema:publication	Virus as Populations
resource representing a document's body	covid:c3f6b652f5bbb394a6ca5eb515027a7ea9806e6f#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/c3f6b652f5bbb394a6ca5eb515027a7ea9806e6f
is schema:about of	named entity 'retroviruses' named entity 'antiviral' named entity 'mutagenic' named entity 'lethal mutagenesis' named entity 'mutation' named entity 'lymphocytic choriomeningitis virus' named entity 'mutagen' named entity 'sequence space' named entity '100 million' named entity 'metabolism' named entity 'cross-resistance' named entity 'mutation' named entity 'combination therapies' named entity 'virology' named entity 'amino acid' named entity 'mutagenic' named entity 'viruses' named entity 'FMDV' named entity 'viruses' named entity 'alleles' named entity 'RNA' named entity 'AMP' named entity 'nucleotide analog' named entity 'picornaviruses' named entity 'fitness landscape' named entity 'NLS' named entity 'Lethal mutagenesis' named entity 'human disease' named entity '5-AZA' named entity 'viruses' named entity 'pathogenic virus' named entity 'lethal mutagenesis' named entity 'human immunodeficiency virus type 1' named entity 'antiviral' named entity 'high-fidelity' named entity 'intracellular' named entity 'consensus sequence' named entity 'antiviral drugs' named entity 'serum' named entity 'quasispecies' named entity 'DAAs' named entity 'mutagenic' named entity 'ribavirin' named entity 'FMDV' named entity 'HCV' named entity 'error-prone' named entity 'protein' named entity 'viruses' named entity 'cell culture' named entity 'bona fide' named entity 'Lethal mutagenesis' named entity 'mutagenic' named entity 'viruses' named entity 'ribavirin' named entity 'viruses' named entity 'ribavirin' named entity 'mutagenesis' named entity 'viral replication' named entity 'nucleotides' named entity 'viral infections' named entity 'quasispecies' named entity 'mRNA' named entity 'selective advantage' named entity 'nucleotide' named entity 'primer' named entity 'genetic information' named entity 'NLS' named entity 'FMDV' named entity 'mutagenic' named entity 'biochemical' named entity 'mouse model' named entity 'nucleic acid' named entity 'quasispecies' named entity 'virology' named entity 'lethal mutagenesis' named entity 'RNA' named entity 'Sacramento' named entity 'pyrimidine analog' named entity 'HIV-1' named entity 'error-prone' named entity 'mutagenesis' named entity 'HCV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software